Last patient completed VAGITOCIN® PK study
PEPTONIC medical today announced that the last patient participating in the VAGITOCIN® pharmacokinetic (PK) study has been discharged after a final visit to the physician
PEPTONIC medical today announced that the last patient participating in the VAGITOCIN® pharmacokinetic (PK) study has been discharged after a final visit to the physician
PEPTONIC medical today announced that it met with the US Food and Drug Administration (FDA) earlier this month in a so called pre-IND meeting. The
PEPONIC medical has signed an agreement with Destum Partners in USA for support in finding suitable collaboration partners. By using a US based consulting company
PEPTONIC has started a collaboration with Clinartis in USA. Clinartis is a consulting company within the clinical/regulatory area. They support us in the work with
A regulatory/scientific, advisory meeting has been performed at the MPA on the 25.3.13. The results from the recently concluded clinical study and the design of
A new formulation patent for oxytocin was approved by the Swedish patent authorities in February 2013. PEPTONIC has received a patent on the new formulation
PEPTONIC medical has concluded a preference share emission which gave 13,6 MSEK. During October 2012 a preference share emission was finished giving 13,6 MSEK. This